SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
66
Lv1
20 积分
2023-10-14 加入
最近求助
最近应助
互助留言
Cancer incidence and mortality in China, 2022
22天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
22天前
已完结
Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary
3个月前
已完结
Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses
4个月前
已完结
PD-1 inhibitors plus chemotherapy as first-line therapy for stage IV ESCC
4个月前
已完结
Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea
4个月前
已完结
Time trends in the incidence of oesophageal cancer in Asia: Variations across populations and histological types
4个月前
已完结
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
6个月前
已完结
Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma?
6个月前
已完结
Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
6个月前
已完结
没有进行任何应助
感谢
4个月前
感谢
4个月前
感谢
4个月前
感谢
4个月前
感谢
6个月前
感谢
6个月前
感谢
6个月前
感谢
6个月前
感谢
7个月前
感谢
7个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论